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The second 360◦ European Meeting on Growth Hormone Disorders, held in Barcelona,
Spain, in June 2017, included a session entitled Pragmatism vs. Curiosity in Genetic
Diagnosis of Growth Disorders, which examined current concepts of genetics and growth
in the clinical setting, in terms of both growth failure and overgrowth. For patients
with short stature, multiple genes have been identified that result in GH deficiency,
which may be isolated or associated with additional pituitary hormone deficiencies, or
in growth hormone resistance, primary insulin-like growth factor (IGF) acid-labile subunit
deficiency, IGF-I deficiency, IGF-II deficiency, IGF-I resistance, and primary PAPP-A2
deficiency. While genetic causes of short stature were previously thought to primarily be
associated with the GH–IGF-I axis, it is now established that multiple genetic anomalies
not associated with the GH–IGF-I axis can result in short stature. A number of genetic
anomalies have also been shown to be associated with overgrowth, some of which
involve the GH–IGF-I axis. In patients with overgrowth in combination with an intellectual
disability, two predominant gene families, the epigenetic regulator genes, and PI3K/AKT
pathway genes, have now been identified. Specific processes should be followed for
decisions on which patients require genetic testing and which genes should be examined
for anomalies. The decision to carry out genetic testing should be directed by the clinical
process, not merely for research purposes. The intention of genetic testing should be to
direct the clinical options for management of the growth disorder.
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INTRODUCTION
Human linear growth continues from the embryonic stage through to adolescence and early
adulthood. During the fetal stage it is mainly controlled by insulin and growth factors and is
affected by maternal health, nutrition and placental function; growth failure at this stage results in a
baby being born small for gestational age. During childhood, the hypothalamic-pituitary control of
the synthesis and release of growth hormone (GH), and the effects of the GH–insulin-like growth
factor (IGF)-I axis on tissues throughout the body, becomes increasingly important in determining
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height growth. The synthesis and release of gonadotropins by
the pituitary, and the increases in sex steroid, GH and IGF-
I concentrations, become significant throughout puberty, and
the pubertal growth spurt continues until near-adult height is
reached. However, normal skeletal growth and development
depends on multiple factors and can be affected by numerous
genetic anomalies, including many that are not associated with
the GH–IGF-I axis. If abnormal growth in either direction occurs
during the pediatric period, children frequently require referral
to an endocrine specialist for assessment and diagnosis.
While there are clearly environmental influences on height,
which may relate to the worldwide increase in average height
through the twentieth century, genetic differences have a major
influence on height variation (1, 2). Height, which is one of
the most heritable phenotypes in humans, shows a binomial
distribution, with abnormalities involving both growth failure
and overgrowth. It is a polygenic trait, and studies in multiple
cohorts of twins have identified ∼700 common variants that
captured ∼60% of heritability (1–5). For 83 identified height-
associated coding variants with minor allele frequencies, effects
of up to 2 cm per allele were observed, which was more than 10-
times the average effect of common variants (4). Results from
such genome-wide association studies have indicated several new
genetic candidates, although the loci of the variants involved
in height are not randomly distributed; examination of genes
enriched for these loci are implicated in novel pathways involved
in growth, some of which contribute to various syndromes of
abnormal skeletal growth (3, 6).
While such studies indicate genes with biological relevance,
genetic testing of children with abnormal growth should not
just involve research to identify gene anomalies associated
with growth defects, but should also provide pragmatic aspects
to determine the diagnostic causes. The following report is
based upon presentations from a meeting, funded by Merck
Healthcare Global Medical Affairs, that aimed to examine the
various genetic causes of growth disorders and the treatment
options. A report from the session on adherence and personalized
GH treatment in the management of growth disorders will be
published separately.
GENETIC TESTING FOR FACTORS
ASSOCIATED WITH SHORT STATURE
Multiple genetic anomalies have been shown to be associated
with growth failure and short stature. The short stature may
be either proportionate or disproportionate, severe or mild,
and have pre-natal and/or post-natal origin (7, 8). While
GH treatment has been approved for use in a number
of different conditions, growth response varies greatly, both
between conditions and within conditions, and it is important to
understand the genetic background to the condition in order to
help predict the response to treatments.
Genetic testing may, therefore, be carried out for practical
reasons to determine the diagnosis and treatment options
in patients with growth failure; however, research is also
necessary to identify genetic abnormalities that are associated
with specific phenotypes linked with short stature. Development
of both pragmatic and research aspects have been carried out
over time, and new genetic associations are being found as
the technologies become more sensitive, cheaper and more
widely applied.
The GH–IGF-I Axis
Growth can be affected at various different developmental stages
and at different points and facets of the GH–IGF-I axis. The
genetic alterations initially identified as being associated with
growth disorders are shown in Figure 1. Genetic disorders may
cause defects in pituitary development during the embryonic
stage, which most frequently results in multiple pituitary
hormone deficiencies. There may also be abnormalities within
the pituitary gland or in hypothalamic signaling, which affect
GH synthesis and release by the pituitary. Finally, there may be
defects in the actions of GH and IGF-I through abnormalities of
receptors in target tissues, causing resistance to the effects of GH
or IGF-I. These defects are usually associated with intrauterine
growth retardation.
GH Deficiency
Isolated GH deficiency or inactivity is a major cause of growth
failure, and multiple genetic abnormalities have been shown over
time using whole genome sequencing approaches (Table 1). In
many familial cases, there are defects in, or deletions of, the gene
coding for GH (GH1) or the GH-releasing hormone receptor
(GHRHR), which lead to either classical GH deficiency or GH
that is biologically inactive (9, 10); in cases where GH is inactive,
as in Kowarski syndrome, the apparent serum concentration
of GH may be normal or even slightly elevated (11). The
condition may also be associated with other syndromic effects,
such as ciliopathies including Alström syndrome, where genetic
abnormalities are associated with functional GH deficiency
(12). Ciliopathies are often associated with skeletal problems,
short stature and nephronophthisis, as seen with IFT172
mutations that cause short-rib thoracic dysplasia (13). While
there are few data on GH status with ciliopathies, a case of
functional GH deficiency, with low IGF-I, that responded to
GH treatment has been described in a patient with an IFT172
mutation (14).
Biallelic mutations in RNPC3 have also been associated with
familial isolated GH deficiency with hypoplasia of the anterior
pituitary (15). The gene encodes a structural component of
the nuclear ribonucleoprotein complex that acts as a minor
spliceosome in the removal of specific introns for a number
of genes. The mutations were identified as being in the RNA
recognition motif of the protein, which binds to U12 and
acts as a bridge between U12 small nuclear RNA and U11
small nuclear RNA of the intron recognition complex. The
growth failure was post-natal and proportionate, with only
mild microcephaly, anterior pituitary hypoplasia, and normal
psychomotor development. GH treatment of these patients was
effective, despite severe short stature and late initiation of
treatment (16).
Patients with isolated GH deficiency are reported to develop
combined pituitary hormone deficiency in about 5–45% of cases
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FIGURE 1 | Genetic defects within the hypothalamo-pituitary axis.
(17, 18). For cases of combined pituitary hormone deficiencies,
the genetics appear to be more complicated and the genetic
etiology is frequently unidentified (Table 2). Genetic defects may
occur sporadically, with no family history, or may be familial;
they may be dominant where a defect in only one allele is
associated with the condition, recessive where abnormalities of
both alleles produce the effect, or X-linked where the defect
comes from an unaffected mother and generally affects only
males (19). Reported frequencies of genetic mutations in patients
with combined pituitary hormone deficiencies varies greatly
between countries and ethnic groups (20). For PROP1, POU1F1,
and HESX1, mutation frequencies are <10% in patients with
sporadic combined pituitary hormone deficiency in Western
Europe, although much higher in Eastern Europe. Despite the
low prevalence in Western Europe, testing for mutations of these
genes is routinely carried out as part of the work-up for such
patients (20).
Anomalies of the classic transcription factor genes cause
very specific profiles of hormone deficiencies due to abnormal
pituitary development; the most prevalent defects in patients
with growth failure are in PROP1, which was reported in a
literature analysis to occur in 6.7% of worldwide sporadic cases
of combined pituitary hormone deficiency and 11.2% when
familial cases were included (21). Mutations of PROP1 cause the
significant clinical feature of pituitary enlargement in some cases,
particularly in childhood and adolescence (22), that sometimes
helps in the diagnosis. Defects in genes for other transcription
factors involved in pituitary development are associated with
other syndromic features. For defects in PITX, SOX2, SOX3, and
SPR, short stature is the predominant phenotype, while for others
(shown in the shaded area of Table 2) there is a more severe
neurological phenotype, and GH deficiency may or may not be
present as one part of the syndrome.
Using a candidate-gene approach to identify mutations in
more than 900 patients with short stature due to GH deficiency,
gene defects could be identified in only about 10% of cases
(23). Mutations were identified more frequently in patients with
combined pituitary hormone deficiencies (14.7%) than in those
with isolated GH deficiency (6.5%). In patients with combined
pituitary hormone deficiencies, the most frequently identified
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TABLE 1 | Genetic abnormalities associated with isolated GH deficiency (GHD) or bio-inactivity.
Disorder Phenotype
MIM
Gene/locus
MIM
Gene/locus Location Clinical features Inheritance Syndromic
Isolated GHD, type 1A 262400 139250 GH1 17q23.3 No serum GH, often anti-GH antibodies AR
Isolated GHD, type IB 612781 139250 GH1 17q23.3 Low serum GH AR
Isolated GHD, type II 173100 139250 GH1 17q23.3 Variable height deficit and pituitary size;
other pituitary deficits can develop
AD
Isolated GHD, type III 307200 300300 BTK Xq22.1 GHD with agammaglobulinemia XLR
Isolated GHD, type IV 612781 139191 GHRHR 7p14.3 Low serum GH AR
Isolated GHD, type V 618160 618016 RNPC3 1p21.1 Severe GHD, hypoplasia anterior
pituitary
AR
Isolated partial GHD 615925 601898 GHSR 3q26.31 Variable serum GH and IGF-I AR, AD
Kowarski syndrome
(bio-inactive GH
syndrome)
262650 139250 GH1 17q23.3 Elevated GH; deficiency of IGF-I,
IGFBP-3 and acid-labile subunit
AD
Alström syndrome 203800 606844 ALMS1 2p13.1 50% of cases are GH-deficient AR Yes
Short-rib thoracic
dysplasia 10 with or
without polydactyly
615630 607386 IFT172 2p23.3 Functional GHD, retinopathy,
metaphyseal dysplasia, hypertension
AR Yes
AD, autosomal dominant; AR, autosomal recessive; XLR, X-linked recessive; MIM, Mendelian inheritance in man coding (https://www.ncbi.nlm.nih.gov/omim); modified fromWit et al. (9).
mutations were in PROP1 (11.6% of patients), followed by LHX3
(1.2%), whereas the gene mutations in patients with isolated
GH deficiency were most frequently found in GH1 (4.8%),
and GHRHR (1.1%). However, the proportion of patients with
identified defects is increasing over time as more genetic variants
are investigated.
Genetic abnormalities also had an effect on clinical outcomes
following GH treatment (23). For 24 patients with an identified
mutation and who reached near-adult height, the height standard
deviation score (SDS) at start of GH treatment was −4.1,
compared with a baseline height SDS of −2.9 in 191 patients
without an identified mutation. The mean near-adult height SDS
was−0.7 in those with a mutation vs.−0.9 in those without, and
the respective mean gain in height SDS at near-adult height was
3.4 vs. 2.0, which was significantly different (p < 0.001). Thus,
those with an identified mutation are likely to be shorter at the
start of GH therapy and have a better response to GH treatment.
For specific gene mutations, patients with a defect inGH1 (n= 4)
had an initial height SDS of −4.2 and a height SDS gain of 3.4 to
reach a near-adult height SDS of−0.8. On average, these patients
remained slightly shorter than normal height. For patients with
a PROP1 mutation, initial height SDS was −3.6, with a gain of
3.6 to reach height SDS 0.0 at near-adult height, and thus were
normal height.
GH Resistance and IGF-I Deficiency
The genetic abnormalities causing GH resistance or IGF-
I deficiency/insensitivity (Table 3) are mainly associated with
intrauterine growth retardation and being born small for
gestational age. The concept of GH resistance and IGF-I
deficiency is becoming more complex and cannot now be
considered as a single clinical entity, but is a continuum
of genetic, phenotypic, and biochemical abnormalities (24).
Genetic variants influence both total IGF-I concentrations and,
through changes in binding proteins, free IGF-I concentrations;
therefore, it is important to determine which methodologies
should be used in the diagnosis. It is often not easy to
identify from the phenotype which genes should be examined,
because serum levels of GH and IGFs may be decreased,
normal or increased in patients with the same genetic defect.
Classic examples of GH resistance are due to mutations
in the GH receptor (GHR) gene, and a large number of
missense and splice mutations and deletions in GHR have
been identified in patients with short stature (24). Mutations
in GHR are most generally associated with Laron syndrome,
in which patients also have very low IGF-I levels (9, 11, 25).
Mutations have also been reported in the signal transducer
and activator of transcription gene, STAT5B, which is part
of the signaling cascade of the GH receptor; in addition to
growth failure, clinical features of these patients frequently
involve immunodeficiency and pulmonary fibrosis (24, 26),
although some missense mutations of STAT5B have recently
been reported to not cause severe immune and pulmonary
problems (27).
More recently, defects in PAPP-A2 have been identified
in children with progressive post-natal growth failure
from two unrelated families (28, 29). The gene encodes
pregnancy-associated plasma protein (PAPP)-A2, which is a
metalloproteinase that cleaves insulin-like growth factor binding
protein (IGFBP)-3 and IGFBP-5. Serum concentrations of total
IGF-I, IGF-II, IGFBP-3, acid-labile subunit, and insulin were all
increased in these patients; however, free IGF-I concentrations
were very low, resulting in lack of negative feedback on GH
synthesis and release. X-radiography of the fibulae, tibiae,
and femurs showed that the long bones were very thin; bone
density was low, with abnormal trabecular structure, and mild to
moderate microcephaly was observed. After 1 year of treatment
with recombinant human IGF-I, two Spanish patients showed
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TABLE 2 | Genetic abnormalities associated with combined pituitary hormone deficiencies (CPHD).
Disorder MIM Gene Clinical features Inheritance Syndromic
CPHD-1 613038 POU1F1 GH, prolactin, variable TSH deficiencies AR, AD
CPHD-2 262600 PROP1 GH, prolactin, TSH, LH, FSH, variable ACTH
deficiencies; pituitary can be enlarged
AR
CPHD-3 221750 LHX3 GH, prolactin, TSH, LH, FSH deficiencies;
sensineural hearing loss; cervical abnormalities;
short stiff neck
AR Yes
CPHD-4 262700 LHX4 GH, TSH, ACTH deficiencies AD, AR
(CPHD-5) Septo–optic
dysplasia
182230 HESX1 Optic nerve hypoplasia, pituitary hypoplasia,
midline abnormalities of brain, absent corpus
callosum, and septum pellucidum
AR, AD Yes
CPHD-6 613986 OTX2 TSH, GH, LH, FSH, variable ACTH, and
prolactin deficiencies
AR, AD
Axenfeld–Rieger syndrome
type 1
180500 PITX2 Coloboma, glaucoma, dental hypoplasia,
protuberant umbilicus, brain abnormalities,
variable pituitary deficiencies
AD Yes
Optic nerve hypoplasia and
CNS abnormalities
206900 SOX2 Variable GHD, hypogonadism, anophthalmia,
developmental delay
AR Yes
X-linked panhypopituitarism 312000,
300123
SOX3 dup GHD or CPHD, mental retardation XLR Yes
Dopa-responsive dystonia
due to sepiapterin reductase
deficiency
612716 SPR Diurnally fluctuating movement disorder,
cognitive delay, neurologic dysfunction, GH,
and TSH deficiencies
AR Yes
Holoprosencephaly 610829 GLI2 Holoprosencephaly, craniofacial abnormalities,
polydactyly, single central incisor, partial
agenesis corpus callosum (or hypopituitarism
only)
AD Yes
Pallister–Hall syndrome 146510 GLI3 Hypothalamic hamartoma, central polydactyly,
visceral malformations
AD Yes
IGSF1deficiency syndrome 300888 IGSF1 Hypothyroidism, TSH, variable GH, and
prolactin deficiencies; macroorchidism
XLR Yes
Netherton syndrome 256500 SPINK5 Variable GH and prolactin deficiency AR Yes
600483 FGF8 Holoprosencephaly, septo-optic dysplasia,
Moebius syndrome
AR Yes
136350 FGFR1 Hypoplasia pituitary, corpus callosum, ocular
defects
AD Yes
607123 PROKR2 Variable hypopituitarism AD Yes
600698 HMGA2 Severe GHD, ectopic posterior pituitary AD
612250 GPR161 Pituitary stalk interruption syndrome,
intellectual disability, sparse hair in frontal area,
hypotelorism, broad nasal root, thick alae nasi,
nail hypoplasia, short fifth finger, 2–3 toe
syndactyly, hypopituitarism
AR Yes
AD, autosomal dominant; AR, autosomal recessive; XLR, X-linked recessive; MIM, Mendelian inheritance in man coding (https://www.ncbi.nlm.nih.gov/omim); shaded rows indicate
conditions with a neurological phenotype where GH deficiency is variable; modified from Wit et al. (9).
a good response of growth velocity, height gain, and trabecular
bone score (30, 31). A report has recently been published on the
history and clinical implications of defects in PAPP-A2 in human
growth (32). The specific degradation of IGFBP-3 and IGFBP-5
by the active metalloproteinase results in release of free IGF-I,
and it has been demonstrated that the identified mutations in
the PAPP-A2 gene, producing inactive PAPP-A2, cause increased
binding of IGF-I and low bioactivity, with consequent reduced
skeletal growth (33).
Identified defects resulting in GH resistance also include
mutations in the IGF1 and IGF2 genes. Abnormalities of IGF1
are rare in humans, with only about 9 cases reported (34, 35),
although both homozygous and heterozygous mutations, and
heterozygous deletions have been identified in patients with
short stature (9, 36, 37); however, homozygous carriers generally
have more severe growth failure than those with heterozygous
defects. Homozygous IGF1 defects that result in complete loss of
functional IGF-I are associated with extreme growth failure, both
pre-natal and post-natal, together with sensorineural deafness,
microcephaly and mental retardation (34–38).
More recently, IGF2 abnormalities have been detected in a
number of patients; the clinical data indicated that IGF-II affects
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TABLE 3 | Genetic abnormalities associated with GH resistance and IGF-I insensitivity.
Syndrome Phenotype
MIM
Gene Inheritance Clinical characteristics Laboratory findings
GH GHBP Prolactin IGF-I IGFBP-3
and ALS
GH Resistance
Laron syndrome 262500 GHR AR (AD) Variable height deficit, mid-facial hypoplasia
GH insensitivity with immunodeficiency 245590 STAT5B AR Mid-facial hypoplasia, immunodeficiency
Multisystem, infantile-onset autoimmune disease 615952 STAT3 activating AD Associated with early-onset multi-organ
autoimmune disease
X-linked severe combined immunodeficiency 300400 IL2RG XLR Non-responding to GH injections
IGF-I deficiency 608747 IGF1 AR Born small for gestational age, microcephaly,
deafness
Severe growth restriction with distinctive facies 616489 IGF2 Patient inheritance Short stature, facial anomalies
Acid labile subunit deficiency 615961 IGFALS AR Mild height deficit
Primary protease deficiency Not yet defined PAPP-A2 AR Moderate microcephaly, skeletal abnormalities
Immunodeficiency 15 615592 IKBKB AR, AD Immunodeficiency
IGF insensitivity
Resistance to IGF-I 270450 IGF1R AD, AR SGA, microcephaly
AD, autosomal dominant; AR, autosomal recessive; XLR, X-linked recessive; MIM, Mendelian inheritance in man coding (https://www.ncbi.nlm.nih.gov/omim); arrows for laboratory findings indicate increase, decrease or no change,
with more than one type of arrow indicating variability; modified from Wit et al. (9).
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FIGURE 2 | Proposed algorithm for screening patients for IGF-related genetic abnormalities.
both pre-natal and post-natal growth and the genetic defects
are associated with clinical features of Silver–Russell syndrome
(39). While IGF2 defects have only recently been identified, it is
possible that they may be more common than initially suspected.
Imprinting disorders, with hypomethylation of genetic control
regions, may result in down-regulation of IGF2 expression by the
paternal allele and are involved in short stature due to both pre-
natal and post-natal growth failure in Silver-Russell syndrome
and Temple syndrome (40). A clinical scoring system has been
derived for Silver-Russell syndrome, and a consensus guideline
stated that first line molecular testing should include analysis
of methylation of the H19/IGF2 domain of the 11p15 region
in patients with a high likelihood of the syndrome (41). The
guideline also concluded that GH treatment improved body
composition and linear growth in these patients.
Defects in IGF1R that result in resistance to the effects of
IGF-I have been described in a number of patients who had
intrauterine growth retardation and failure of catch-up growth
(9, 42, 43). The defects can occur in the external domain,
the internal domain or in the transmembrane domain of the
receptor. The condition is associated with microcephaly and
psychomotor retardation in some, but not all, cases and there
may be other clinical pathologies, such as impaired glucose
tolerance, dysmorphic features, and cardiac abnormalities, but
the pattern is inconsistent (42, 44); patients with homozygous
mutations may show stronger syndromic features compared with
heterozygous carriers (45). Recently, a case was described with
both a deletion of IGF1R and a duplication of the paternal IGF2
region, resulting in appropriate pre-natal growth but retardation
of post-natal growth, indicating the key role of IGF-II in fetal
growth and the more important role of the GH–IGF-I axis in
post-natal growth (46). In children with IGF1R defects, IGF-I
concentration is generally high and above normal during GH
treatment, although this may be considered acceptable owing to
the reduced sensitivity.
As a result of these studies of patients with GH resistance,
an algorithm was designed to try to predict which patients
should have genetic screening for mutations (Figure 2). This
is difficult because of the inconsistent patterns of clinical and
laboratory features (Table 3). For patients with intrauterine
growth retardation, possibly with microcephaly, and who have
sporadic occurrence of psychomotor retardation and deafness,
it may be worthwhile to look for mutations in IGF1; however,
genotyping is somewhat ambiguous in these patients. Patients
with familial occurrence of short stature related to being born
small for gestational age who have high IGF-I should be checked
for abnormalities of IGF1R. A recent study has suggested a
clinical score for selecting patients for genetic testing of IGF1R
defects, and indicated that testing should be carried out for
children born small for gestational age, with low birth weight
and/or length, and who remained short, had microcephaly and
had IGF-I SDS >0 at presentation (47). Patients with low
serum IGF-II concentration and clinical features of Silver–Russell
syndrome, although not necessarily full Silver–Russell syndrome,
should be examined for defects in IGF2 (48).
In patients shown to have severe primary IGF-I deficiency,
recombinant human IGF-I appears to be effective and has
been approved for use (7, 49). IGF-I has also been tested
in combination with GH in patients with reduced IGF-I
concentrations and GH sufficiency (50). Combined GH and
IGF-I treatment has also been suggested for patients with
GH insufficiency plus IGF-I deficiency due to heterozygous
dominant-negativeGHR variants (51). However, IGF-I treatment
has not been approved for use in such cases, and the specific
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clinical conditions in which GH, IGF-I, or the combination of
these, may be effective need to be identified; genetic testing
should help to determine which treatment approach may be
useful to improve linear growth (7, 52).
For 51 patients born small for gestational age and with failure
of catch-up growth, treatment with GH resulted in a median gain
in height SDS of 0.64 in the first year; for nine patients born small
for gestational age and without catch-up growth due to genetic
defects that resulted in dysfunctional IGF-I receptors, the median
first year height SDS response was 0.24 (Pfäﬄe R, unpublished
data). The difference between the overall cohort and the patients
with abnormal IGF1R was significant (p = 0.013). However, the
GH dose given to the patients with dysfunctional IGF-I receptors
was kept slightly lower than the dose for the patients born small
for gestational age because of concerns of excessive serum IGF-
I concentration, which could have partially accounted for the
difference. A variable response to GH treatment of children with
IGF1R deletions or mutations was seen in other studies, with
GH in most, though not all, having a beneficial effect (44). The
response in children with an IGF1R defect was suggested to be
less than the response seen in short children born SGA due to
other causes, although adult height gain was similar and may be
related to duration of treatment (47). While GH treatment for
children born small for gestational age and without spontaneous
catch-up growth is indicated to be initiated only at age 4 years
or above, starting GH treatment at a very young age (<4 years)
in such children has been described to be more effective than in
those who were older at GH initiation (53), at least during 3 years
of therapy.
Genetic Anomalies Not Associated With
the GH–IGF-I Axis
Genome wide association studies and next-generation
sequencing have indicated a large number of new genes
associated with short stature, although in many cases the exact
mechanism remains unknown (54). Until relatively recently,
it was thought that linear growth in childhood was primarily
influenced by the GH–IGF-I axis and that abnormal growth due
to genetic causes were related to defects in that system. However,
it has recently been suggested that rather than focusing on the
GH–IGF-I axis, genetic studies should be more concerned with
the biology of the growth plate (55). Cases reported as idiopathic
short stature may be due to genetic disorders previously only
considered to be associated with skeletal dysplasias.
Hypochondroplasia and achondroplasia are the most
common skeletal dysplasias that cause short stature and are
associated with abnormalities of the FGFR3 gene (56, 57).
Fibroblast growth factor receptor 3 negatively regulates
chondrogenesis and mutations in the gene result in increased
activity, which disrupts normal functioning of the proliferation
zone of the growth plates and impairs bone elongation. While
heritability is autosomal dominant, the majority of cases
arise from spontaneous mutations and ∼80% of cases are
born to parents of average height. Diagnosis is generally at
birth or in early infancy. No formal diagnostic criteria have
been published although there are well-defined clinical and
radiological characteristics, including rhizomelic short stature
with short limbs and short fingers, limited elbow extension,
small chest, macrocephaly, and flattened mid-facial features
(56). GH treatment is not an approved treatment, except in
Japan, but increases growth velocity over the first few years.
Very few studies have followed patients to adult height, but the
long-term effect appears to be limited (58). The Indian hedgehog
paracrine system also controls chondrocyte proliferation and
differentiation and defects can result in short stature (57, 59).
Autosomal dominant mutations in the IHH gene result in
mild skeletal dysplasias with brachydactyly, but patients may
be diagnosed as born small for gestational age or as idiopathic
short stature with defects only identified through whole exome
sequencing, and the growth failure appeared to be improved by
GH in the short-term (59).
Aggrecan is a key component of the cartilage extracellular
matrix of the growth plate and articular surfaces. Abnormalities
in the ACAN gene, which encodes the proteoglycan, results
in proportionate or mildly disproportionate short stature,
generally with advanced bone aging and premature growth
cessation (60, 61). ACAN defects are a common cause of
idiopathic short stature and born small for gestational age;
homozygous abnormalities result in severe skeletal dysplasia
while heterozygous defects cause milder skeletal dysplasia (61,
62). A clinical scoring system has been proposed to identify
children likely to have an ACAN mutation, although there is a
variable spectrum of phenotypes (63). GH treatment has been
reported to be effective, but very few studies have been carried
out (62, 63).
Patients with anomalies of the short stature homeobox-
containing (SHOX) gene also show a wide spectrum of
phenotypes, from Leri-Weill dischondrosteosis, with mesomelia
and Madelung deformity, to non-specific short stature (64).
SHOX deficiency is one of the most common genetic defects
associated with short stature in humans. In patients with
idiopathic short stature, the prevalence of anomalies in the SHOX
gene or its regulatory elements, including deletions, duplications
and insertions, has been reported to range from about 6 to 22%,
with increasing prevalence reported as genetic tests have become
more accurate (65). The severity of the condition does not appear
to relate to specific gene anomalies, and individuals within a
family could have the same defect but different phenotype (65,
66); however, SHOX deletions or mutations are more associated
with Leri-Weill syndrome whereas enhancer region defects are
more likely to be associated with less severe features of idiopathic
short stature (67). SHOX protein expressed by the gene is a
transcription factor that regulates the expression of various other
genes in the growth plate, including ACAN and FGFR3; while the
mechanism has not been completely elucidated, SHOX protein
influences chondrocyte proliferation, hypertrophy, maturation,
and apoptosis, thus regulating long bone growth (65, 68).
The SHOX gene is located in the pseudoautosomal region
and normal physiology requires two copies of the gene, with
haploinsufficiency occurring when only one functioning copy
of the gene is present. Short stature due to SHOX deficiency
is, therefore, a frequent occurrence in children with Turner
syndrome, with all or part of one X-chromosome missing.
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A need for screening of SHOX gene defects may be predicted
from abnormal limb-to-trunk ratios, x-radiography and family
history, and predictive algorithms have been proposed (64, 65).
Where clinical features are severe, deletions are seen in about
80 to 90% and genetic evaluations should include chromosomal
microarray analysis or SNP array analysis; for patients with less
severe characteristics, exome sequencing is used more frequently
(64, 65). GH treatment of children with SHOX deficiency is an
approved indication and is effective in improving adult height by
7 to 10 cm (65, 69).
SHOX gene anomalies are found in ∼70% of children
with Leri-Weill dischondrosteosis (68). However, similar
phenotypic features, including short stature but without
Madelung deformity, occur with defects in the natriuretic
peptide receptor-B gene, NPR2. NPR-B is the receptor for
C-type natriuretic peptide, which is a regulator of chondrocyte
differentiation and hypertrophy in the growth plates, and may be
one of the genes activated by SHOX proteins (65). NPR2 defects
have been identified in about 2 to 6% of cases of idiopathic
short stature (70, 71). Biallelic loss of function mutations cause
Maroteaux-type acromesomelic dysplasia, while heterozygous
mutations result in less severe short stature (70, 71). Therefore,
patients may have severe skeletal dysplasia or non-specific
skeletal abnormalities, but phenotype characteristics of patients
with NPR2 gene defects are currently not well established (72),
and patients with short stature due to NPR2 defects may only
be detected where a relative has acromesomelic dysplasia (71).
Very few patients with NPR2 defects have currently been treated
off-label with GH, but increased growth appeared to be modest
and further studies would be required to demonstrate long-term
efficacy (70, 72).
GENETIC FACTORS ASSOCIATED WITH
OVERGROWTH
Overgrowth With No Associated
Intellectual Problems
By contrast to gene defects that cause short stature, alternative
defects in the same genes can result in overgrowth. Gain-of-
function mutations in NPR2 have been identified in a number
of patients with skeletal overgrowth, with associated features
of scoliosis and macrodactyly, with markedly large big toes
(71, 73, 74). The ligand for the receptor is C-type natriuretic
peptide (CNP) and overproduction due to translocation of the
NPPC gene also caused tall stature withmacrodactyly and skeletal
dysplasia (75, 76). The mechanism of excess skeletal growth due
to increased activation of the CNP/NRPB system was reported to
be through overproduction of cyclic guanosine monophosphate
within the growth plate chondrocytes (73, 74, 76).
Beckwith-Wiedemann syndrome is one of the most common
overgrowth conditions and is the converse of Silver-Russell
syndrome, due tomolecular anomalies in the chromosome 11p15
imprinting region (47, 77, 78). Duplications of the imprinting
region is associated with over-expression of the IGF2 gene and
patients are reported to have both pre-natal and post-natal
overgrowth, with associated anomalies including macroglossia,
organomegaly, abdominal wall defects, neonatal hypoglycemia,
and predisposition to embryonic tumors (77). Because of the
increased risk of tumors associated with the condition, a
consensus meeting devised a scoring system based on both
cardinal and suggestive clinical features of the syndrome. This
allowed identification of patients requiring molecular testing
and provided a flowchart for analysis of gain of methylation
within the 11p15 genetic region and copy number variation (78).
The guidelines also provided recommendations for management
of various complications, including overgrowth that continues
beyond childhood, although that occurs in only 43 to 65%
of patients.
Overgrowth, with either gigantism occurring before
epiphyseal growth plate fusion or acromegaly due to excessive
skeletal growth at any time, can be caused by a number of genetic
defects that result in benign adenomas, with excess GH and
IGF-I synthesis and release. Gigantism and acromegaly are rare
in children, although pediatric cases have aggressive features;
identified genetic conditions include, amongst others, familial
isolated pituitary adenoma and the more recently described
X-linked acrogigantism (X-LAG), which have been reviewed
recently and an algorithm for genetic testing and counseling
proposed (79, 80). Because such diagnoses are generally made
at a young age and there is frequently resistance to medical
therapy, analysis of the genetic basis is needed to predict
therapeutic options. The most common condition is familial
isolated pituitary adenoma, which is usually diagnosed in
childhood or adolescence, requires at least two cases of pituitary
adenomas in the family and the tumor is large and invasive
(81). Inactivating mutations or deletions of the aryl hydrocarbon
receptor-interacting protein gene, AIP, predispose patients to the
condition and are the most frequently identified genetic cause of
pituitary gigantism (82). Prevalence of AIP mutations in cases
of sporadic pituitary adenomas is reported to be ∼4%, but may
be up to 20% in children and adolescents with gigantism and/or
macroadenomas (83). Although no genetic defects are found in a
majority of patients with familial isolated pituitary adenoma (84),
a recent study found novel variants of the MEN1 gene in some
cases where no defects in AIP were observed (85). Patients with
sporadic pituitary adenomas and identified AIP mutations have
been mainly young males, with median age of emergence at 17.5
years, the tumor tends to be larger than in patients without AIP
mutations and tumors were more often resistant to somatostatin
analogs and required surgical intervention (80, 82, 83).
X-LAG syndrome is very rare, but is the most frequently
identified cause of gigantism in pre-pubertal patients, with
diagnosis generally before the age of 3 years (80, 86). The
condition is characterized by increased linear growth and weight
that can be seen before 12 months of age, although gestational
size may be normal; patients often have increased appetite and
hunger and most identified cases also had hyperprolactinemia
(82, 86). Because of the very early onset of overgrowth, adult
height may be greatly increased at >4.5 SDS (87, 88). Both GH
and IGF-I are markedly elevated, but GH releasing hormone is
also elevated and the adenomas remain sensitive suggesting that
therapeutic antagonists of the GH releasing hormone receptor
could reduce the excess GH secretion (87, 89). The condition is
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TABLE 4 | Genetic abnormalities identified among 710 patients with OGID syndromes.
Gene family
Variant gene
Proportion of total
patients
Associated condition MIM Inheritance
Epigenetic regulator genes
NSD1 240 cases, 34% Sotos syndrome 117550 AD
EZH2 34 cases, 4.8% Weaver syndrome 277590 AD
DNMT3A 18 cases, 2.5% Tatton-Brown–Rahman syndrome 615879 AD
CHD8 12 cases, 1/7% Autism susceptibility 615032 AD
HIST1H1E 5 cases, 0.7% Rahman syndrome 617537 AD
EED 2 cases, 0.3% Cohen Gibson syndrome 617561 AD
PI3K/mTOR pathway genes
PTEN 16 cases, 2.3% PTEN hamartoma tumor syndrome 158350 AD
PPP2R5D 3 cases, 0.4% Mental retardation 616355 AD
MTOR 2 cases, 0.3% Smith-Kingsman syndrome 616638 AD
AKT3 1 case, 0.1% Megalencephaly-polymicrogyria-polydactyl-hydrocephalus syndrome 2 615937 AD
PIK3CA 1 case, 0.1% PIK3CA-related overgrowth syndrome Multiple Unknown
Undetermined pathway genes
NFIX 14 cases, 2.0% Marshall-Smith syndrome 602535 AD
BRWD3 7 cases, 1.0% X-linked mental retardation 300659 XLR
GPC3 2 cases, 0.3% Simpson-Golabi-Behmel syndrome 312870 XLR
AD, autosomal dominant; XLR, X-linked recessive; MIM, Mendelian inheritance in man coding (http://www.omim.org); adapted from information in Tatton-Brown et al. (91).
linked to a germline micro-duplication of chromosome Xq26.3
and is associated with the GPR101 gene (86–88). A number
of mutations in GPR101 have also been identified in patients
with sporadic acromegaly (86, 90). GPR101 encodes a G-protein
coupled receptor, the function of which has not currently
been fully elucidated, that is predominantly expressed in the
hypothalamus and fetal pituitary glands, and it may have a role
in pituitary ontogenesis (86, 87, 90). The disorder is X-linked,
arising spontaneously in most cases; because index cases are
generally female and more than 70% of cases are female, it has
been suggested that affected hemizygous male embryos may be
less viable, although familial cases from mother to son have been
reported (79, 82, 87). X-LAG syndrome does not have any specific
association with intellectual disability. However, a chromosome
Xq26 microduplication was found in a 4-year old boy referred
for examination for X-LAG (91). The genetic duplications are
detected using array comparative genome hybridization (82, 87);
this is normally clinical grade analysis, where duplications may
be smaller than the assay resolution, and when assayed by
high definition molecular cytogenetics the duplication did not
include the GPR101 gene (91). The patient did not show the
phenotype of gigantism or GH excess and the study showed
the importance of the correct genetic assay and provided
supporting evidence for GPR101 being the gene involved
in X-LAG.
Overgrowth With Intellectual Disability
Overgrowth-intellectual disability (OGID) syndromes are a
family of genetic disorders characterized by excessive growth
(height and/or head circumference ≥2 SD above the mean
compared with the age-related peer group) in combination
with an intellectual disability (92). Over the last decade, since
the introduction of next-generation sequencing technologies
that permit the examination of thousands of genes in a single
experiment, the genetic cause of many OGID syndromes has
been determined. A gene discovery study of patients with OGID
syndromes, reported in 2017, included 710 participants and
identified 14 different genes among 50% of affected individuals
(93). Children with overgrowth phenotypes without intellectual
disability were excluded from the study. Two key OGID gene
families were identified: the epigenetic gene regulator family (six
genes, 44% of the overall patients) and the PI3K/mTOR pathway
gene family (five genes, 6% of the overall patients); in addition,
variants in three genes involved in, as yet, undetermined
pathways were identified (Table 4).
The proteins encoded by genes involved in epigenetic
regulation were (1) histone methyltransferases targeting specific
lysine residues of histone tails (NSD1, EED, EZH2), (2) a
DNA methyltransferase (DNMT3A), and (3) genes involved in
chromatin remodeling (CHD8) and stabilization of higher-order
chromatin structures (HIST1H1E).
Of the OGID genes identified in the study,NSD1was the most
frequently mutated (240 children, 34% overall). Nuclear receptor
binding SET domain protein 1 (NSD1) catalyzes the methylation
of lysine residue 36 of histone H3 (H3K36) and, to a lesser degree,
lysine residue 20 of histone H4 (H4K20), a methylation mark
primarily associated with transcriptional activation (94). NSD1
variants cause Sotos syndrome (MIM 117550), associated with
increased growth, an intellectual disability and a characteristic
facial appearance with a broad forehead, down-slanting palpebral
fissures, long thin face, tall chin, malar flushing and sparse fronto-
temporal hair (95, 96).
EZH2 and EED encode components of the polycomb
repressor complex 2 (PRC2), which catalyzes the methylation of
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histone 3 at lysine 27 (H3K27) associated with transcriptional
repression (97). Pathogenic variants within EZH2 and EED cause
very similar OGID phenotypes; respectively, Weaver syndrome
(MIM 277590) and Cohen Gibson syndrome (MIM 617561),
characterized by tall stature, variable intellectual disability and
characteristic facial appearance of “stuck-on” chin, horizontal
skin crease, and hypertelorism (96, 98, 99).
DNMT3A pathogenic variants cause Tatton-Brown–Rahman
overgrowth syndrome (TBRS; MIM 615879) (100). Children
with TBRS characteristically have variable intellectual disability,
autism spectrum disorders and increased growth (93, 100–
102). A range of different medical issues are additionally
associated with TBRS, including hypermobility of joints, obesity,
kyphoscoliosis, and congenital cardiac anomalies (100).
HIST1H1E encodes the linker histone H1.4, and recently five
unrelated probands were identified with de novo heterozygous
frameshift variants (protein truncated variants, PTVs) that were
clustered in a 12 base-pair region of the carboxy-terminal domain
(93). Histone H1.4 is one of the 11 histones that mediate
formation of chromatin structures that regulate gene expression.
It is hypothesized that the clustered PTVs all generate the same
open-reading frame, with the shorter mutant protein associated
with a reduced net positive charge compared to the wild type,
thereby disrupting normal binding to negatively-charged DNA
(93, 103). Patients with HIST1H1E pathogenic variants have a
variable intellectual disability and a characteristic appearance of
high hairline and frontal bossing.
With regard to the PI3K/mTOR pathway genes, PTEN
pathogenic variants have been an established cause of
PTEN hamartoma tumor syndrome (PHTS; MIM 158350),
also known for many years as Bannayan-Riley-Ruvalcaba
syndrome in childhood (92, 96). The encoded PTEN protein
is a negative regulator of the PI3K/mTOR pathway, and
affected children are macrocephalic, and may have an
intellectual disability and autistic spectrum disorder. In
addition, they have a predisposition to develop cancers in
adulthood (Cowden syndrome) (104). PIK3CA pathogenic
variants are primarily associated with macrocephaly and
asymmetric growth, which may be progressive (92, 96).
Treatment with drugs that block the PI3K/mTOR pathway,
such as sirolimus and everolimus that are already in use as
anti-cancer agents, have been shown in vitro and in animal
models to be effective in reducing the progressive overgrowth
and may potentially improve cognition (93, 105, 106).
Such treatments in humans have shown varying success
in reducing the regional overgrowth, although the side-
effect profile, most notably the increased infection rate, is
significant [(106, 107), and ClinicalTrials.gov: NCT02991807
and NCT00971789].
CONCLUSIONS
Human height follows a binomial distribution; however,
individuals that lie at the extremes of the distribution may
potentially have problems that require investigation. Height is a
highly heritable classic polygenic trait and, therefore, part of any
investigation frequently involves genetic analysis. Genome-wide
studies have identified ∼700 common associated variants with
effects on height and 83 minor allele variants that had effects
on growth of up to 2 cm per allele. Many genes have effects
on the GH–IGF-I axis, and new genes are constantly being
added to the list. Research is fundamental to increase knowledge
of the genes and mechanisms involved in the pathophysiology
of different diseases. However, in the clinical setting, genetic
studies are required to progress from phenotype, auxology,
and hormone measurements to more precise genetic diagnoses
and treatments.
New technologies, such as whole exome sequencing and whole
genome sequencing, are increasing the speed, precision and
availability of genetic diagnoses, with decreasing costs (108–
110). Some areas of the genome have limited capture by whole
exome sequencing, making it difficult to go from a diagnosis
based on phenotype and medical background to proof from
genotype. Therefore, next-generation sequencing techniques,
such as targeting exome sequencing, are being developed, to
target specific collections of candidate genes with the use of
chromosomal microarrays to detect copy number variations
(16, 111). Such techniques can be directed to make a specific
diagnosis, while whole exome and whole genome sequencing
may be more useful for research purposes to identify new genetic
variations associated with specific conditions: identifying the
genes involved in combined pituitary hormone deficiency may
be more useful as a scientific interest to provide new insights
into pathogenesis and novel treatment strategies; identifying the
genes involved in Turner syndrome will be more useful from a
diagnostic point of view, when appropriate genetic counseling
and treatment monitoring can be carried out; and detecting the
genes involved in GH resistance could be useful for both scientific
research and for identifying potential clinical consequences.
While short stature is a frequent cause of referral to a pediatric
endocrinologist, screening for tall stature is generally considered
a lower priority. However, it is important to identify pathological
causes of gigantism and overgrowth, particularly because certain
genetic conditions may be resistant to medical therapy or
predispose to tumors. With regard to the OGID syndromes,
while there is considerable phenotypic overlap between many
of the individual conditions, patients with epigenetic regulator
gene variants more frequently have tall stature in association
with macrocephaly, whereas those with PI3K/mTOR pathway
gene variants more usually have isolated macrocephaly. Research
into the genetic basis of these syndromes provides a background
understanding of the normal regulation and development of
growth. On a practical basis, knowledge of the genotype in
patients with OGID syndromes and in patients with growth
failure is likely to be increasingly useful for pharmacogenomics
and gene-directed therapies.
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